VIR

Vir Biotechnology, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $11.17
52-Week Range: $4.82 – $11.94
Market Cap: $1.94B
P/E (TTM): —
EPS (TTM): -1.76
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.97
PEG Ratio: —
Return on Equity: -26.08%
Return on Assets: -14.51%
Gross Margin: -59.39%
Operating Margin: 30.75%
Profit Margin: -83.00%
Current Ratio: 6.04
Debt/Equity: 0.09
Total Debt: $93.27M
Free Cash Flow: $-38.89M
Revenue Growth: 19582.50%
Earnings Growth: —
Enterprise Value: $1.45B

VIR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.58B	$39.49M	$63.71M	$66.52M
Cost of Revenue	$146.32M	$2.77M	$845.00K	$26.00K
Gross Profit	$1.43B	$36.73M	$62.87M	$66.49M
Research & Development	$474.65M	$579.72M	$506.50M	$455.97M
Selling, General & Admin	$161.76M	$174.44M	$119.03M	$92.07M
Operating Expenses	$601.09M	$707.48M	$615.04M	$546.00M
Operating Income	$833.07M	-$670.75M	-$552.17M	-$479.51M
EBITDA	$839.85M	-$651.29M	-$537.61M	-$467.83M
Pretax Income	$754.28M	-$628.19M	-$523.11M	-$437.77M
Income Tax	$238.44M	-$13.08M	-$1.15M	$217.00K
Net Income	$515.84M	-$615.06M	-$521.96M	-$437.99M
Diluted EPS	3.83	-4.59	-3.83	-3.16
Diluted Shares	134.81M	134.13M	136.25M	138.52M

VIR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$848.63M	$241.58M	$222.95M	$232.19M
Receivables	$0.00	—	—	—
Current Assets	$2.52B	$1.59B	$1.04B	$514.08M
Total Assets	$2.80B	$1.92B	$1.40B	$1.00B
Current Liabilities	$511.03M	$175.41M	$119.66M	$92.81M
Total Debt	$127.97M	$124.54M	$97.89M	$97.85M
Total Liabilities	$724.13M	$328.82M	$248.43M	$237.55M
Retained Earnings	$377.24M	-$237.82M	-$759.78M	-$1.20B
Shareholders' Equity	$2.08B	$1.59B	$1.15B	$765.28M
Working Capital	$2.01B	$1.41B	$922.80M	$421.26M

VIR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$1.66B	-$778.78M	-$446.35M	-$391.78M
Capital Expenditure	-$68.01M	-$21.57M	-$7.30M	-$4.83M
Free Cash Flow	$1.60B	-$800.36M	-$453.65M	-$396.61M
Depreciation & Amortisation	$6.78M	$19.45M	$14.56M	$11.68M
Stock-Based Compensation	$102.08M	$111.32M	$78.46M	$49.07M
Investing Cash Flow	-$1.19B	$164.63M	$499.37M	$310.37M
Financing Cash Flow	$34.76M	$7.48M	$4.39M	$3.79M
Net Change in Cash	$504.55M	-$606.68M	$57.40M	-$77.63M

VIR Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.03M	-$65.00K	$63.76M	-$41.00K	$238.94M
Cost of Revenue	$11.00K	-$11.00K	$26.00K	—	$0.00
Gross Profit	$1.02M	-$54.00K	$63.73M	—	$238.94M
Research & Development	$97.51M	$151.46M	$88.35M	$108.92M	$135.28M
Selling, General & Admin	$22.28M	$22.23M	$23.62M	$23.34M	$30.20M
Operating Expenses	$119.61M	$173.39M	$111.66M	$132.25M	$165.47M
Operating Income	-$118.59M	-$173.44M	-$47.92M	-$132.29M	$73.47M
EBITDA	-$115.67M	-$170.44M	-$45.02M	-$129.48M	$76.27M
Pretax Income	-$110.79M	-$162.97M	-$43.06M	-$125.53M	$80.26M
Income Tax	$170.00K	$168.00K	-$137.00K	$170.00K	$179.00K
Net Income	-$110.96M	-$163.14M	-$42.92M	-$125.69M	$80.08M
Diluted EPS	-0.80	-1.17	-0.31	-0.85	0.47
Diluted Shares	138.45M	138.93M	139.23M	147.36M	168.88M

VIR Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$211.10M	$170.08M	$232.19M	$274.16M	$278.73M
Current Assets	$735.71M	$545.68M	$514.08M	$522.99M	$573.74M
Total Assets	$1.19B	$1.02B	$1.00B	$1.03B	$1.21B
Current Liabilities	$105.00M	$75.22M	$92.81M	$73.56M	$94.96M
Total Debt	$102.23M	$100.17M	$97.85M	$95.58M	$93.27M
Total Liabilities	$245.06M	$223.35M	$237.55M	$212.82M	$232.31M
Retained Earnings	-$991.71M	-$1.15B	-$1.20B	-$1.32B	-$1.24B
Shareholders' Equity	$947.47M	$796.10M	$765.28M	$812.76M	$982.49M
Working Capital	$630.70M	$470.46M	$421.26M	$449.43M	$478.78M

VIR Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$120.22M	-$167.57M	-$25.88M	-$132.39M	$123.33M
Capital Expenditure	-$2.54M	-$317.00K	-$348.00K	-$390.00K	-$32.00K
Free Cash Flow	-$122.76M	-$167.89M	-$26.22M	-$132.78M	$123.29M
Depreciation & Amortisation	$2.92M	$3.00M	$2.90M	$2.81M	$2.80M
Stock-Based Compensation	$12.45M	$11.36M	$11.21M	$12.09M	$12.39M
Investing Cash Flow	$56.46M	$40.45M	$86.65M	$11.84M	-$197.14M
Financing Cash Flow	$2.05M	$102.00K	$1.04M	$162.52M	$78.38M
Net Change in Cash	-$61.72M	-$127.02M	$61.81M	$41.97M	$4.56M

Market Snapshot

About

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing immunological treatments for infectious diseases. The company uses antibody platform technologies to develop therapies for diseases including hepatitis B, influenza, HIV, and COVID-19. Vir leverages deep insights into viral immunology to create potentially transformative treatments.